Trials / Completed
CompletedNCT01689233
Safety and Efficacy Study Evaluating TRx0237 in Subjects With Mild Alzheimer's Disease
Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 18-Month Safety and Efficacy Study of TRx0237 in Subjects With Mild Alzheimer's Disease
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 800 (actual)
- Sponsor
- TauRx Therapeutics Ltd · Industry
- Sex
- All
- Age
- 89 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine the safety and efficacy of TRx0237 in the treatment of subjects with mild Alzheimer's Disease.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | TRx0237 200 mg/day | TRx0237 100 mg tablets will be administered twice daily. |
| DRUG | Placebo | Placebo tablets will be administered twice daily. The active placebo tablets include 4 mg of TRx0237 as a urinary and fecal colorant to maintain blinding; hence the placebo group will receive a total of 8 mg/day of TRx0237. |
Timeline
- Start date
- 2012-10-01
- Primary completion
- 2016-05-01
- Completion
- 2016-05-01
- First posted
- 2012-09-21
- Last updated
- 2018-03-14
Locations
95 sites across 12 countries: United States, Australia, Belgium, Canada, Croatia, Finland, France, Germany, Italy, Netherlands, Spain, United Kingdom
Source: ClinicalTrials.gov record NCT01689233. Inclusion in this directory is not an endorsement.